Chenguang Biotechnology: Announcement on the progress of providing guarantees for bank borrowings of subsidiaries
Securities code: 300138 Securities abbreviation: Chenguang Biotechnology Announcement number: 2026-046
Chenguang Biotechnology Group Co., Ltd.
Announcement on the progress of providing guarantees for bank borrowings of subsidiaries
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Overview of guarantee situation
Chenguang Biotechnology Group Co., Ltd. (referred to as the "Company") held the 22nd meeting of the fifth board of directors on March 29, 2026 and April 28, 2026. The 2025 Annual Shareholders' Meeting was held on the same day, and the "Proposal on Financing Guarantees between the Company and its Subsidiaries or Subsidiaries" was reviewed and approved. It was agreed that the company and its subsidiaries at all levels within the scope of the consolidated statements would apply to financing institutions for various financing business balances not exceeding 7 billion yuan from the date of review and approval of the 2025 annual shareholders' meeting to the date of the 2026 annual shareholders' meeting; the financing guarantee method involves guarantees between entities within the scope of the company's consolidated statements: the company's guarantee balance for the financing of subsidiaries at all levels within the scope of the consolidated statements shall not exceed 28 billion, of which: the balance of guarantees provided to subsidiary Xinjiang Chenguang Biotechnology Co., Ltd. (referred to as "Xinjiang Chenguang") and its subsidiaries within the scope of consolidated statements does not exceed 2.4 billion yuan (including mutual guarantees by various entities within the scope of Xinjiang Chenguang's consolidated statements), and the balance of guarantees provided to other subsidiaries does not exceed 400 million yuan. The company's shareholders meeting authorized the management to make specific adjustments to the guaranteed subsidiaries and their guarantee limits based on the asset-liability ratio, financing credit, etc. of each subsidiary within the scope of the consolidated statements, on the premise that the balance of financing guarantees does not exceed 2.8 billion yuan (relevant documents have been announced on cninfo.com on March 31, 2026, and April 28, 2026).
2. Progress of external guarantees
The company’s guarantees for bank loans of its subsidiaries have changed. The details are as follows:
- Based on its own operating capital needs, Tumushuke Shengyuan Biotechnology Co., Ltd. (referred to as "Tumushuke Shengyuan", formerly "Morning Biotechnology Group Tumushuke Co., Ltd.", a wholly-owned subsidiary of Xinjiang Chenguang, and a holding subsidiary of the company after penetration) recently submitted a working capital loan application to the Kashgar Branch of China Construction Bank Co., Ltd. (hereinafter referred to as "Kashgar CCB"). After verification, Kashgar Construction Bank approved the loan application of Tumushuke Shengyuan Company, and Tumushuke Shengyuan Company signed a "RMB Working Capital Loan Contract" with Kashgar Construction Bank. The amount is 50 million yuan, and the guarantee method is: company guarantee guarantee.
The company and Kashgar Construction Bank signed a "Guarantee Contract" on the above-mentioned loan matters. The guarantee amount is: 5,000 Ten thousand yuan; the guarantee method is: joint liability guarantee; the guarantee period is: from the date the "Guarantee Contract" takes effect to three years after the expiration of the debt performance period under the main contract; the scope of the guarantee is: all debts under the main contract, including but not limited to all principal, interest (including compound interest and penalty interest), liquidated damages, compensation, judgments or mediation documents and other effective legal documents that should be doubled during the delay in performance. Debt interest, other amounts payable by the debtor to the creditor (including but not limited to relevant handling fees, telecommunications fees, miscellaneous fees, relevant bank fees that foreign beneficiaries refuse to bear, etc.), expenses incurred by the creditor to realize creditor's rights and security rights (including but not limited to litigation fees, arbitration fees, property preservation fees, travel expenses, execution fees, appraisal fees, auction fees, notary fees, service fees, announcement fees, attorney fees, etc.).
If the debt under the main contract matures or the creditor declares that the debt is due early in accordance with the provisions of the main contract or the law, the debtor fails to perform in full and on time, or the debtor violates other provisions of the main contract, or circumstances under the main contract endanger the creditor's rights and cause the creditor to exercise its guarantee rights, the company shall immediately assume the guarantee liability within the scope of the guarantee.
- Based on its own operating capital needs, and following the resolution of the company’s 2024 Annual General Meeting of Shareholders, Chenguang Biotechnology Group Karamay Co., Ltd. (hereinafter referred to as “Karamay Chenguang”, currently renamed as “Euphratica euphratica Shengyuan Biotechnology Co., Ltd.”, a wholly-owned subsidiary of Xinjiang Chenguang, and a holding subsidiary of the company after penetration) applied for 5,000 from the Kuitun City Branch of Bank of China Co., Ltd. (referred to as “BOC Kuitun”) in the early stage. Ten thousand yuan of working capital was borrowed and some loans were made. The guarantee method is: company guarantee guarantee.
The company and Kuitun Bank of China signed a "Guarantee Contract" on the above-mentioned loan matters. The guaranteed main creditor's rights include principal, interest, liquidated damages, compensation, expenses for realizing the creditor's rights, losses caused to the creditor due to the debtor's default and all other payable expenses; the guarantee method is: joint liability guarantee; the guarantee period is: three years from the expiration of the repayment period of the main creditor's rights (see December 2025 for details) The "Announcement on the Progress of Providing Guarantees for Bank Loans of Subsidiaries" was disclosed on cninfo.com on March 9).
Recently, Karamay Chenguang repaid the above-mentioned loan from Kuitun Bank of China on schedule. All the loans guaranteed under the "Guarantee Contract" have been repaid, and the company has reduced its corresponding guarantee obligation of 50 million yuan.
3. Cumulative external guarantees
After the changes in the above guarantee situation, the company and its subsidiaries have cumulatively resolved to provide financing guarantees to entities within the scope of the consolidated statements of RMB 2.80 billion, and the signed agreement guarantee amount is RMB 2,013 million, accounting for 59.40% of the company's latest audited net assets (before this change in guarantee situation, the balance of the signed agreement guarantees was RMB 2,013 million). Among them: it was decided to provide a total guarantee of RMB 2.40 million for the subsidiary Xinjiang Chenguang and its subsidiaries within the scope of the consolidated statements (including mutual guarantees by all entities within the scope of Xinjiang Chenguang's consolidated statements), and the guaranteed amount of the signed agreement was RMB 1.913 million, accounting for 56.45% of the company's most recent audited net assets (before this change in the guarantee situation, the balance of the guaranteed guarantee under the signed agreement was RMB 1.913 million).
There is no change in the guarantees provided by the company and its holding subsidiaries for the financing of joint-stock companies outside the consolidated statement. The shareholders' meeting resolved that the total guarantee limit is 25 million yuan, of which: the balance of the signed agreement guarantee is 11.5825 million yuan, accounting for 0.34% of the company's latest audited net assets.
The company and its subsidiaries have no overdue external guarantees.
Announcement hereby
Board of Directors of Chenguang Biotechnology Group Co., Ltd.
May 6, 2026